Alison Reid

4.2k total citations · 1 hit paper
34 papers, 2.7k citations indexed

About

Alison Reid is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Alison Reid has authored 34 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Alison Reid's work include Prostate Cancer Treatment and Research (18 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Cancer, Lipids, and Metabolism (6 papers). Alison Reid is often cited by papers focused on Prostate Cancer Treatment and Research (18 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Cancer, Lipids, and Metabolism (6 papers). Alison Reid collaborates with scholars based in United Kingdom, United States and Australia. Alison Reid's co-authors include Johann S. de Bono, Gerhardt Attard, David P. Dearnaley, Elizabeth Folkerd, Mitch Dowsett, Gloria Lee, Christopher Parker, David Olmos, Stan B. Kaye and Nikhil Babu Oommen and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Alison Reid

32 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Alison Reid

Since Specialization

Citations

This map shows the geographic impact of Alison Reid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Reid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Reid more than expected).

Fields of papers citing papers by Alison Reid

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Reid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Reid. The network helps show where Alison Reid may publish in the future.

Co-authorship network of co-authors of Alison Reid

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Reid. A scholar is included among the top collaborators of Alison Reid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Reid. Alison Reid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The contemporary management of prostate cancer 2025 ·CA A Cancer Journal for Clinicians ·(unknown), Peter C. Albertsen, (unknown), Amar U. Kishan, (unknown), (unknown), Angela Pathmanathan, Alison Reid, Oliver Sartor, Nicholas van As, Jochen Walz, Alison Tree	2
2	Meta-analysis of Germline Whole-exome Sequencing in 1435 Cases of Testicular Germ Cell Tumour to Evaluate Disruptive Mutations Under Dominant, Recessive, and X-linked Inheritance Models 2025 ·European Urology Open Science ·(unknown), Charlie F Rowlands, (unknown), Alice Garrett, Chey Loveday, (unknown), (unknown), Kevin Litchfield, Alison Reid, Robert Huddart, Peter Broderick, Richard S. Houlston, Clare Turnbull	0
3	Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial 2024 ·Clinical Oncology ·Priyanka Patel, (unknown), Alison Reid, Chris Parker, Julia Murray, Angela Pathmanathan, (unknown), (unknown), Yae‐Eun Suh, J. Frew, (unknown), Isabel Syndikus, (unknown), Nina Tunariu, Alison Tree	2
4	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice 2022 ·Frontiers in Oncology ·Priyanka Patel, Nina Tunariu, Daniel S. Levine, Johann S. de Bono, Rosalind A. Eeles, Vincent Khoo, Julia Murray, Christopher Parker, Angela Pathmanathan, Alison Reid, Nicholas van As, Alison Tree	5
5	Features and Management of Late Relapse of Nonseminomatous Germ Cell Tumour 2021 ·European Urology Open Science ·(unknown), (unknown), Michael O’Callaghan, (unknown), Robert Huddart, Erik Mayer, Alison Reid, David Nicol	2
6	Trabectedin for advanced soft tissue sarcomas: optimizing use 2014 ·Therapeutics and Clinical Risk Management ·Alison Reid, Charlotte Benson, (unknown)	2
7	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study 2012 ·The Lancet Oncology ·David Olmos, Daniel Brewer, Jeremy Clark, Daniel C. Danila, Chris Parker, Gerhardt Attard, Martin Fleisher, Alison Reid, Elena Castro, Shahneen Sandhu, (unknown), Nikhil Babu Oommen, Suzanne Carreira, Charles G. Drake, Robert J. Jones, Colin S. Cooper, Howard I. Scher, Johann S. de Bono	84
8	Primary rectal melanoma 2011 ·Journal of Surgical Case Reports ·Alison Reid, (unknown), (unknown), (unknown)	7
9	The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study 2010 ·British Journal of Cancer ·L. Rhoda Molife, Peter C.C. Fong, (unknown), Alison Reid, Heather M. Shaw, Laura Vidal, (unknown), Vasilios Karavasilis, Timothy A. Yap, David Olmos, James Spicer, Sophie Postel‐Vinay, Da Yin, Allan Lipton, Laurence M. Demers, Kim Leitzel, Antonio Gualberto, Johann S. de Bono	69
10	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors 2009 ·Molecular Cancer Therapeutics ·Richard D. Baird, Jos Kitzen, Paul A. Clarke, André Planting, (unknown), Alison Reid, (unknown), Luis López Lázaro, Begoña de las Heras, Ian Judson, Stan B. Kaye, Ferry A.L.M. Eskens, Paul Workman, Johann S. de Bono, Jaap Verweij	33
11	Abiraterone acetate: the novel application of a CYP450c17 inhibitor to the treatment of both prostate and breast cancer 2009 ·Elizabeth Folkerd, G. Attard, David P. Dearnaley, John W. Hunt, Gal Maier, A. Molina, David Olmos, (unknown), (unknown), Alison Reid, (unknown), (unknown), Mitch Dowsett	1
12	A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors 2009 ·Clinical Cancer Research ·Alison Reid, Andrew Protheroe, Gerhardt Attard, (unknown), Laura Vidal, James Spicer, Heather M. Shaw, (unknown), (unknown), Leon Hooftman, Adrian L. Harris, Johann S. de Bono	29
13	A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin 2009 ·Cancer Chemotherapy and Pharmacology ·Malcolm Ranson, Heather Shaw, Jürgen Wolf, Marta Hamilton, (unknown), Emma Dean, Alison Reid, Ian Judson	30
14	Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) 2009 ·Annals of Oncology ·L. Rhoda Molife, Gerhardt Attard, Peter C.C. Fong, Vasilios Karavasilis, Alison Reid, Stephen G. Patterson, Charles E. Riggs, Celestia S. Higano, Walter M. Stadler, William McCulloch, David P. Dearnaley, Chris Parker, Johann S. de Bono	147
15	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven breakdown → 2008 ·Journal of Clinical Oncology ·Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, J. W. Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono	666
16	A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours 2008 ·British Journal of Cancer ·Sarah P. Blagden, L. Rhoda Molife, (unknown), Miranda Payne, Alison Reid, Andrew Protheroe, Lakshmi Vasist, Daphne Williams, Chester L. Bowen, Steven J. Kathman, Jeffrey P. Hodge, Mohammed M. Dar, Johann S. de Bono, Mark R. Middleton	63
17	Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC) 2007 ·Molecular Cancer Therapeutics ·Gerhardt Attard, Alison Reid, Rajesh Kumar Sinha, R. Molife, Florence I. Raynaud, Mitch Dowsett, Mary Barrett, Emilda Thompson, Timothy A. Yap, S. Settatree, Vanessa Martins, Christopher Parker, David P. Dearnaley, Elizabeth Folkerd, Gloria Lee, Johann S. de Bono	1
18	Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu) 2007 ·European Journal of Cancer ·Alison Reid, Laura Vidal, Heather Shaw, Johann S. de Bono	126
19	Complex patterns of ETS gene alteration arise during cancer development in the human prostate 2007 ·Oncogene ·J Clark, Gerhardt Attard, Sameer Jhavar, Penny Flohr, Alison Reid, Johann S. de Bono, Rosalind A. Eeles, Peter T. Scardino, Jack Cuzick, Gabrielle Fisher, Matthew Parker, Christopher S. Foster, Daniel M. Berney, Gyula Kovács, Christopher S. Cooper	112
20	Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. 2005 ·Clinical Cancer Research ·Sarah P. Blagden, (unknown), R. Molife, Miranda Payne, Alison Reid, Andrew Protheroe, Steven J. Kathman, Dallas Williams, Carolyn J. Bowen, Jeffrey P. Hodge, (unknown), Johann S. de Bono, Mark R. Middleton	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact